术前系统免疫炎症指数和中性粒细胞/淋巴细胞比值与卵巢癌患者预后的关系
The Prognostic Value of Systemic Immune-Inflammation Index and Neutrophil to Lymphocyte Ratio on the Prognosis of Ovarian Cancer
摘要: 目的：探讨系统免疫炎症指数(SII)和外周血中性粒细胞/淋巴细胞计数比值(NLR)对卵巢癌患者无进展生存期(PFS)的评估价值。方法：回顾性分析2012年6月至2015年6月于青岛大学附属医院就诊123例卵巢癌患者的临床资料，应用受试者工作特征(ROC)曲线确定SII和NLR的最佳临界值，Kaplan-Meier生存曲线评估SII和NLR对卵巢癌PFS的影响。单因素和多因素分析确定影响卵巢癌PFS的预后因素。结果：卵巢癌患者中，根据ROC曲线确定SII和NLR的最佳临界值，SII和NLR高水平组的PFS显著低于SII和NLR低水平组(P < 0.001)，高水平组与低水平组在年龄和病理类型上没有明显差异，但高水平组在分化程度和FIGO分期中期别更晚，更易发生淋巴结转移。COX多因素分析显示分化程度差、FIGO分期晚期、SII及NLR高水平为影响卵巢癌患者PFS的独立危险因素。结论：SII和NLR是影响卵巢癌患者PFS的独立因素，SII和NLR高水平提示预后不良，因此SII和NLR有潜能作为预测卵巢癌预后的新指标。
Abstract: Objective: The study aimed to investigate the prognostic value of systemic immune-inflammation index (SII) and neutrophil to lymphocyte ratio (NLR) in patients with ovarian cancer (OC). Method: A total of 123 OC patients were retrospectively analyzed from June 2012 to June 2015 in the Affiliated Hospital of Qingdao University. We use receiver operating characteristic (ROC) curve to calculate the optimal cut-off values for SII and NLR. Kaplan-Meier survival curve was used to estimate the association between SII, NLR and progression-free survival (PFS) among OC patients. Results: In OC patients, the PFS in high SII and NLR groups was significantly lower than low SII and NLR group (P < 0.001). Age and history were not found to be different between high SII, NLR groups and low groups, while advanced FIGO stage, low grade and positive lymph node were associated with high SII and NLR groups. Advanced FIGO stage, high grade, high SII and NLR were evaluated as independent risk factors according to COX multivariate analysis. Conclusion: SII and NLR are independent factors for prognosis of OC patients, and increased SII and NLR are related to a poor prognosis. Therefore, SII and NLR are potential factors to predict the prognosis of OC patients.
文章引用：赵飞, 丁朝霞, 陈爱平. 术前系统免疫炎症指数和中性粒细胞/淋巴细胞比值与卵巢癌患者预后的关系[J]. 临床医学进展, 2021, 11(3): 1125-1131. https://doi.org/10.12677/ACM.2021.113161

参考文献

[1] Siegel, R.L., Miller, K.D. and Jemal, A. (2020) Cancer Statistics, 2020. CA: A Cancer Journal for Clinicians, 70, 7-30. [Google Scholar] [CrossRef] [PubMed]
[2] Balkwill, F. and Mantovani, A. (2001) Inflammation and Cancer: Back to Virchow? The Lancet, 357, 539-545. [Google Scholar] [CrossRef] 
[3] Greten, F.R. and Grivennikov, S.I. (2019) Inflammation and Cancer: Triggers, Mechanisms, and Consequences. Immunity, 51, 27-41. [Google Scholar] [CrossRef] [PubMed]
[4] Stotz, M., Gerger, A., Eisner, F., et al. (2013) Increased Neutrophil-Lymphocyte Ratio Is a Poor Prognostic Factor in Patients with Primary Operable and Inoperable Pancreatic Cancer. British Journal of Cancer, 109, 416-421. [Google Scholar] [CrossRef] [PubMed]
[5] Uchinaka, E.I., Amisaki, M., Yagyu, T., et al. (2019) Prognostic Significance of Pre-Surgical Combined Platelet Count and Neutrophil-Lymphocyte Ratio for Patients with Hepatocellular Carcinoma. In Vivo, 33, 2241-2248. [Google Scholar] [CrossRef] [PubMed]
[6] Pedersen, M.M., Donskov, F., Pedersen, L., et al. (2020) Elevated Neutrophil-Lymphocyte Ratio Combined with Hyponatremia Indicate Poor Prognosis in Renal Cell Carcinoma. Acta Oncologica, 59, 13-19. [Google Scholar] [CrossRef] 
[7] Berardi, R., Santoni, M., Rinaldi, S., et al. (2019) Pre-Treatment Systemic Immune-Inflammation Represents a Prognostic Factor in Patients with Advanced Non-Small Cell Lung Cancer. Annals of Translational Medicine, 7, 572. [Google Scholar] [CrossRef] [PubMed]
[8] Wang, L., Wang, C., Wang, J., et al. (2017) A Novel Systemic Immune-Inflammation Index Predicts Survival and Quality of Life of Patients after Curative Resection for Esophageal Squamous Cell Carcinoma. Journal of Cancer Research and Clinical Oncology, 143, 2077-2086. [Google Scholar] [CrossRef] [PubMed]
[9] Chen, L., Yan, Y., Zhu, L., et al. (2017) Systemic Immune-Inflammation Index as a Useful Prognostic Indicator Predicts Survival in Patients with Advanced Gastric Cancer Treated with Neoadjuvant Chemotherapy. Cancer Management and Research, 9, 849-867. [Google Scholar] [CrossRef] 
[10] Mano, Y., Shirabe, K., Yamashita, Y., et al. (2013) Preoperative Neutrophil-to-Lymphocyte Ratio Is a Predictor of Survival after Hepatectomy for Hepatocellular Carcinoma: A Retrospective Analysis. Annals of Surgery, 258, 301-305. [Google Scholar] [CrossRef] 
[11] Hu, B., Yang, X.R., Xu, Y., et al. (2014) Systemic Immune-Inflammation Index Predicts Prognosis of Patients after Curative Resection for Hepatocellular Carcinoma. Clinical Cancer Research, 20, 6212-6222. [Google Scholar] [CrossRef] 
[12] Kim, J. and Bae, J.S. (2016) Tumor-Associated Macrophages and Neutrophils in Tumor Microenvironment. Mediators of Inflammation, 2016, Article ID: 6058147. [Google Scholar] [CrossRef] [PubMed]
[13] Gay, L.J. and Felding-Habermann, B. (2011) Contribution of Platelets to Tumour Metastasis. Nature Reviews Cancer, 11, 123-134. [Google Scholar] [CrossRef] [PubMed]
[14] Cools-Lartigue, J., Spicer, J., McDonald, B., et al. (2013) Neutrophil Extracellular Traps Sequester Circulating Tumor Cells and Promote Metastasis. Journal of Clinical Investigation, 123, 3446-3458.
[15] Browning, L., Patel, M.R., Horvath, E.B., et al. (2018) IL-6 and Ovarian Cancer: Inflammatory Cytokines in Promotion of Metastasis. Cancer Management and Research, 10, 6685-6693. [Google Scholar] [CrossRef] 
[16] Miao, Y., Yan, Q., Li, S., et al. (2016) Neutrophil to Lymphocyte Ratio and Platelet to Lymphocyte Ratio Are Predictive of Chemotherapeutic Response and Prognosis in Epithelial Ovarian Cancer Patients Treated with Platinum-Based Chemotherapy. Cancer Biomarkers, 17, 33-40. [Google Scholar] [CrossRef] 
[17] Nie, D., Gong, H., Mao, X. and Li, Z. (2019) Systemic Immune-Inflammation Index Predicts Prognosis in Patients with Epithelial Ovarian Cancer: A Retrospective Study. Gynecologic Oncology, 152, 259-264. [Google Scholar] [CrossRef] [PubMed]

为你推荐